Deciphera Pharmaceuticals, Inc. (DCPH) Entering an Endless Pit?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) went up to recover about 34.34% since recording its record low price of $18.55. The stock experienced -3.75% slump, arriving at $24.92 on 01/11/2019. During the day, the stock price traveled from $24.73 to $26. This company shares are 100.64% off its target price of $50 and the current market capitalization stands at $975.12M. The recent change has given its price a 8% lead over SMA 50 and -45.36% deficit over its 52-week high. The stock witnessed -8.18% declines, -14.89% declines and -35.17% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found DCPH’s volatility during a week at 8.57% and during a month it has been found around 8.9%.

Deciphera Pharmaceuticals, Inc. (DCPH) Top Holders

Institutional investors currently hold around $517 million or 56% in DCPH stock. Look at its top three institutional owners. New Leaf Venture Partners, L.L.C. owns $102.28 million in Deciphera Pharmaceuticals, Inc., which represents roughly 10.49% of the company’s market cap and approximately 19.78% of the institutional ownership. Similar statistics are true for the second largest owner, Orbimed Advisors Llc, which owns 1,953,500 shares of the stock are valued at $48.68 million. The third largest holder is Sv Health Investors, Llc, which currently holds $42.77 million worth of this stock and that ownership represents nearly 4.39% of its market capitalization.

Deciphera Pharmaceuticals, Inc. 13F Filings

At the end of September reporting period, 49 institutional holders increased their position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by some 2,472,677 shares, 38 decreased positions by 1,881,050 and 15 held positions by 16,392,458. That puts total institutional holdings at 20,746,185 shares, according to SEC filings. The stock grabbed 14 new institutional investments totaling 639,623 shares while 16 institutional investors sold out their entire positions totaling 412,558 shares.

Multiple company employees have indulged in significant insider trading. Deciphera Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO Kelly Thomas Patrick has sold 5,000 shares of Deciphera Pharmaceuticals, Inc. (DCPH) in trading session dated Jan. 07, 2019. These shares are worth $125,900 and were traded at $25.18 each. The SEC filing shows that Ratcliffe Liam performed a purchase of 375,000 shares. The Director, 10% Owner added these shares by way of transaction on Oct. 02, 2017. The company’s shares were assimilated at $17 per share worth to an investment of some $6,375,000 on account of Ratcliffe Liam.

10% Owner, New Leaf Venture Management Ii, purchased 375,000 common shares of Deciphera Pharmaceuticals, Inc. (DCPH) in the open market. In a transaction dated Oct. 02, 2017, the shares were bought at an average price of $17, giving away a sum of $6,375,000. After this purchase, 2,146,308 common shares of DCPH are directly owned by the insider, with total stake valued at $53,485,995.

Deciphera Pharmaceuticals, Inc. (DCPH) Analyst Guide

Several analysts have released their opinion on Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 7 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2.09 average brokerage recommendation.